Comparison of temozolomide-capecitabine to 5-fluorouracile-dacarbazine in 247 patients with advanced digestive neuroendocrine tumors using propensity score analyses
Conclusion. PFS may be longer with 5FU-DTIC than TEM-CAP in patients with advanced NET. Although patients often prefer oral chemotherapy, 5FU-DTIC is a relevant alternative. A randomized comparison is needed to confirm these results.
Source: Neuroendocrinology - Category: Endocrinology Source Type: research
More News: Brain | Chemotherapy | Endocrinology | France Health | Neurology | Pancreas | Temodar | Xeloda